WP
SGTX

Woodline Partners’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Woodline Partners’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,631
Closed -$193K – 836
2021
Q3 		$193K Hold
2,631
– – ﹤0.01% 576
2021
Q2 		$367K Hold
2,631
– – 0.01% 481
2021
Q1 		$764K Buy
2,631
+136
+5% +$54.1K 0.02% 375
2020
Q4 		$1.56M Buy
+2,495
New +$1.13M 0.04% 202

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Woodline Partners's SGTX Position: Q4 2021 in Review

Woodline Partners sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q4 2021, closing a stake of 2,631 shares — an estimated $193K sold.

Woodline Partners first reported a position in SGTX in Q4 2020 and held it in 4 quarters. The position peaked at $1.56M in Q4 2020. 50 funds tracked by Wall St. Rank hold SGTX as of Q4 2021.

  • Woodline Partners reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Woodline Partners sold 2,631 Sigilon Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $193K.
  • Woodline Partners first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
  • Woodline Partners's Sigilon Therapeutics, Inc. Common Stock position peaked at $1.56M in Q4 2020.
  • 50 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Woodline Partners's 13F filing for Q4 2021, filed 14 Feb 2022.